Crinetics Pharmaceuticals, Inc. (CRNX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

10/25

Growth 4 Margin 1 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

10
Crinetics (CRNX) Q1 2026: Palsonify Achieves 70% Reimbursement, Broadening Acromegaly Market Penetration
May 08, 2026
11
Crinetics (CRNX) Q4 2025: $1.4B Cash Position Extends Runway for Pipeline and Pelsonify Launch
February 27, 2026
11
Crinetics (CRNX) Q3 2025: 70% of Early Palsonify Scripts from Community Docs Signals Broad Uptake Path
November 07, 2025
9
Crinetics (CRNX) Q2 2025: $1.2B Cash Runway Secured as Palsonify Launch Nears FDA Decision
August 08, 2025
8
Crinetics (CRNX) Q1 2025: R&D Spend Jumps 43% as Paltusotine Launch Nears, Pipeline Push Accelerates
July 05, 2025
Crinetics Pharmaceuticals (CRNX) Q4 2024: $1.4B Cash Fuels Pipeline Expansion and Commercial Launch Readiness
February 27, 2025

Browse all companies